AI Article Synopsis
- The study develops and characterizes kNGR peptide-conjugated lipid-polymer nanoparticles aimed at delivering the anticancer drug Paclitaxel (PTX) specifically to target tumors.
- The nanoparticles (PLNs-kNGR-NPs) showed greater cytotoxicity and increased apoptosis in cancer cells compared to other formulations, indicating enhanced drug delivery and uptake.
- In experiments with Balb/c mice, these nanoparticles achieved a significant tumor volume reduction of 59.7%, demonstrating their potential for effective cancer treatment in tumors that overexpress CD13 receptors.
Article Abstract
The present study aims to design, develop and characterize kNGR (Asn-Gly-Arg) peptide-conjugated lipid-polymer-based nanoparticles for the target-specific delivery of anticancer bioactive(s), i.e., Paclitaxel (PTX). The kNGR-PEG-DSPE conjugate was synthesized and characterized by using spectral analysis. The dual-targeted PLGA-lecithin-PEG core-shell nanoparticles (PLNs-kNGR-NPs) were synthesized using a modified nanoprecipitation process, and their physiological properties were determined. The results support that, compared to other NPs, PLNs-kNGR-NPs are highly cytotoxic, owing to higher apoptosis and intracellular uptake. The significance of rational nanoparticle design for synergistic treatment is shown by the higher tumor volume inhibition percentage rate (59.7%), compared to other designed formulations in Balb/c mice in the HT-1080 tumor-induced model. The overall results indicate that the PLNs-kNGR-NPs-based hybrid lipid-polymer nanoparticles present the highest therapeutic efficacy against solid tumor overexpressing the CD13 receptors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320317 | PMC |
| http://dx.doi.org/10.3390/pharmaceutics14071401 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A kNGR Peptide-Tethered Lipid-Polymer Hybrid Nanocarrier-Based Synergistic Approach for Effective Tumor Therapy: Development, Characterization, Ex-Vivo, and In-Vivo Assessment.
Pharmaceutics
July 2022
Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo 2007, Australia.
Article Synopsis
- The study develops and characterizes kNGR peptide-conjugated lipid-polymer nanoparticles aimed at delivering the anticancer drug Paclitaxel (PTX) specifically to target tumors.
- The nanoparticles (PLNs-kNGR-NPs) showed greater cytotoxicity and increased apoptosis in cancer cells compared to other formulations, indicating enhanced drug delivery and uptake.
- In experiments with Balb/c mice, these nanoparticles achieved a significant tumor volume reduction of 59.7%, demonstrating their potential for effective cancer treatment in tumors that overexpress CD13 receptors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!